News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS) And Auxilium Pharmaceuticals (AUXL) Announce FDA Acceptance Of Supplemental Filing Seeking An Update Of Prescribing Information For STENDRA (Avanafil)


1/21/2014 8:52:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif. and CHESTERBROOK, Pa., Jan. 21, 2014 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) and Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL) today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental application that proposes to revise the STENDRAâ„¢ (avanafil) prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with Erectile Dysfunction." The PDUFA date for the supplemental filing is September 20, 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES